ArticleNeurosurgery2026
Mortality Outcomes After Spinal Cord Stimulation: A 10-Year Survival Analysis of 330 Patients With Chronic Neuropathic Pain.
Article in Neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesSpinal cord stimulation (SCS) is an established but intricate therapy for neuropathic pain. Chronic pain is associated with increased mortality; however, the impact of successful SCS treatment on mortality remains unreported. In this retrospective case-controlled study, we present survival and cause-specific mortality data for patients trialed for SCS.
methodsThe primary outcome was cause-specific mortality in our cohort of 330 consecutive patients, aged 65 years or younger, referred to Kuopio University Hospital for persistent spinal pain syndrome type 2, complex regional pain syndrome, or other neuropathic pain. An SCS device was implanted in 256 patients but later explanted in 78 cases. To compare mortality, 979 matched controls and causes of death were sourced from a national registry.
resultsDuring a median follow-up of 9.1 years, 28 patients and 39 matched controls died. The 10-year mortality rate was increased in the trial-only group (hazard ratio [HR] = 2.34; CI 1.11-5.09, P = .03) and the explanted SCS group (HR = 3.57; CI 1.83-6.98, P < .001), whereas no increased mortality was observed in the permanent SCS group compared with matched controls (HR = 1.41; CI 0.68-2.91, P = .35). The most frequent causes of death were malignant neoplasms (27%) and external causes (27%).
conclusionIncreased mortality was observed in patients with a negative SCS trial or explanted SCS devices, whereas patients with successful SCS treatment experienced no excess mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.